{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000104","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.480488+00:00","generated_at":"2026-05-21T09:09:37.609400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zentalis Q1 2025 cash $332.5M; first patient dosed in DENALI Part 2 azenosertib trial","bullets":["Cash $332.5M (incl. $12.2M Immunome stock) at March 31, 2025; runway into late 2027.","First patient dosed in DENALI Part 2a for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer.","Topline data from DENALI Part 2 expected by year-end 2026; potential for accelerated approval.","R&D expenses $27.2M vs $49.6M YoY; total operating expenses $45.6M including $7.8M restructuring.","Prior Part 1b data: ORR 34.9%, median DOR 6.3 months in evaluable Cyclin E1+ PROC patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000104","json":"https://secwatch.observer/filing/0001725160-25-000104.json","markdown":"https://secwatch.observer/filing/0001725160-25-000104.md","text":"https://secwatch.observer/filing/0001725160-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/0001725160-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000104/zntl-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:09:37.609400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}